monolaurin (CID 14871) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(20)
 
 
Inactive(157)
 
 
Inconclusive(2)
 
 
Unspecified(21)
 
 
Top Targets:
DUF3652(2)
 
 
Geminin(2)
 
 
PMP22 Claudin(2)
 
 
Menin(2)
 
 
NR LBD ROR li..(2)
 
 
BioAssay Types:
Literature(109)
 
 
 
 
Confirmatory(88)
 
 
 
Screening(2)
 
 
BioActivity Types:
Potency(32)
 
 
 
IC50(1)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 139    Data Row: 200   Total Pages: 4   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103598785]
 Antifungal activity against Candida albicans SC5314 assessed as => 3-log drop in number of fungal CFU/ml at 100 ug/ml after 4 to 8 hrs [AID509403, Type: Literature]
View
2
[SID103598785]
 Antifungal activity against Candida glabrata assessed as => 3-log drop in number of fungal CFU/ml at 500 ug/ml after 4 to 8 hrs [AID509404, Type: Literature]
View
3
[SID103598785]
 Antifungal activity against Candida pseudotropicalis kefyr assessed as => 3-log drop in number of fungal CFU/ml at 100 ug/ml after 4 to 8 hrs [AID509405, Type: Literature]
View
4
[SID103598785]
 Antifungal activity against Candida parapsilosis assessed as => 3-log drop in number of fungal CFU/ml at 500 ug/ml after 4 to 8 hrs [AID509406, Type: Literature]
View
5
[SID103598785]
 Antifungal activity against Candida tropicalis assessed as => 3-log drop in number of fungal CFU/ml at 500 ug/ml after 4 to 8 hrs [AID509407, Type: Literature]
View
6
[SID103598785]
 Antifungal activity against Candida krusei assessed as => 3-log drop in number of fungal CFU/ml at 500 ug/ml after 4 to 8 hrs [AID509408, Type: Literature]
View
7
[SID103598785]
 Antifungal activity against Candida albicans SC5314 clinical isolate at 100 ug/ml after 24 hrs [AID509409, Type: Literature]
View
8
[SID103598785]
 Antibacterial activity against Gardnerella vaginalis assessed as => 3-log drop in number of fungal CFU/ml at 1 to 10 ug/ml after 24 hrs [AID509410, Type: Literature]
View
9
[SID103598785]
 Antifungal activity against Candida-mediated vaginal infection in woman at 0.5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509411, Type: Literature]
View
10
[SID103598785]
 Antibacterial activity against Gardnerella vaginalis-mediated vaginal infection in woman at 0.5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509412, Type: Literature]
View
11
[SID103598785]
 Antifungal activity against Candida-mediated vaginal infection in woman at 5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509414, Type: Literature]
View
12
[SID103598785]
 Antibacterial activity against Gardnerella vaginalis-mediated vaginal infection in woman at 5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509415, Type: Literature]
View
13
[SID103598785]
 Antiviral activity against HIV1 infected in human T cells assessed as inhibition of viral infection at 100 ug/mL [AID580463, Type: Literature]
View
14
[SID103598785]
 Bactericidal activity against Helicobacter at >=20 ug/ml [AID580464, Type: Literature]
View
15
[SID103598785]
 Bactericidal activity against Haemophilus at >=20 ug/ml [AID580465, Type: Literature]
View
16
[SID103598785]
 Bactericidal activity against Gardnerella at >=20 ug/ml [AID580466, Type: Literature]
View
17
[SID103598785]
 Inhibition of Staphylococcus aureus MN8 infection induced IL-8 production in human HVEC assessed as at 100 ug/ml by enzyme-linked immunosorbent assay [AID580471, Type: Literature]
View
18
[SID103598785]
 Suppression of cell viability loss of Lactobacillus crispatus in stationary phase culture at 100 ug/ml after 48 hrs [AID580469, Type: Literature]
View
19
[SID103598785]
 Suppression of cell viability loss of Lactobacillus casei in stationary phase culture at 100 ug/ml after 48 hrs [AID580476, Type: Literature]
View
20
[SID103598785]
 Growth inhibition of Staphylococcus aureus MN8 using 5% compound-formulated gel after 24 hrs [AID580478, Type: Literature]
View
21
[SID103598785]
IC50 100Antiviral activity against HIV NL-Lai infected in human TZM-bl cells assessed as inhibition of viral infection after 24 hrs by luciferase assay [AID612430, Type: Literature]
View
22
[SID103598785]
 Cytotoxicity against human MIAPaCa2 cells after 7 days by MTT assay [AID402193, Type: Literature]
View
23
[SID103598785]
 Cytotoxicity against human PC3 cells after 7 days by MTT assay [AID402192, Type: Literature]
View
24
[SID103598785]
 Cytotoxicity against human A498 cells after 7 days by MTT assay [AID402191, Type: Literature]
View
25
[SID103598785]
 Toxicity against brine shrimp [AID402190, Type: Literature]
View
26
[SID26757947]
 qHTS profiling for inhibitors of Plasmodium falciparum proliferation [AID504749, Type: Literature]
View
27
[SID103598785]
 Effect on growth of Lactobacillus crispatus using 5% compound-formulated gel after 24 hrs [AID580477, Type: Literature]
View
28
[SID103598785]
 Effect on growth of Lactobacillus casei at 20 to 100 ug/ml after 24 hrs [AID580470, Type: Literature]
View
29
[SID103598785]
 Effect on growth of vaginal Lactobacillus flora in rhesus monkey administered twice daily dose of 5% compound-formulated gel for first 8 weeks followed by 3-weeks rest period and subsequent once daily dose for 1 weeks measured 6 months post dose [AID580472, Type: Literature]
View
30
[SID103598785]
 Effect on growth of vaginal coagulase negative staphylococci flora in rhesus monkey administered twice daily dose of 5% compound-formulated gel for first 8 weeks followed by 3-weeks rest period and subsequent once daily dose for 1 weeks measured 6 months post dose [AID580473, Type: Literature]
View
31
[SID103598785]
 Toxicity in rhesus monkey assessed as induction of vaginal mucosal lesions administered twice daily dose of 5% compound-formulated gel for first 8 weeks followed by 3-weeks rest period and subsequent once daily dose for 1 weeks measured 6 months post dose by extensive colposcopy [AID580474, Type: Literature]
View
32
[SID103598785]
 Effect on lactic acid production in Lactobacillus crispatus at 50 ug/ml after 8 to 24 hrs [AID580475, Type: Literature]
View
33
[SID103598785]
 Effect on growth of Lactobacillus crispatus at 20 ug/ml after 24 hrs [AID580467, Type: Literature]
View
34
[SID103598785]
 Effect on growth of Lactobacillus crispatus at 50 ug/ml after 24 hrs [AID580468, Type: Literature]
View
35
[SID103598785]
 Toxicity in woman with Candida-mediated vaginal infection assessed as adverse events at 5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509423, Type: Literature]
View
36
[SID103598785]
 Toxicity in woman with Lactobacillus-mediated vaginal infection assessed as adverse events at 5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509424, Type: Literature]
View
37
[SID103598785]
 Toxicity in woman with Gardnerella vaginalis-mediated vaginal infection assessed as adverse events at 5% treated via intravaginal gels every 12 hrs for 2 days measured post application [AID509425, Type: Literature]
View
38
[SID103598785]
 Effect on growth in Staphylococcus aureus MN8 at 10.7 mM after 24 hrs (Rvb = 100%) [AID555336, Type: Literature]
View
39
[SID103598785]
 Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 10.7 mM after 24 hrs relative to control [AID555368, Type: Literature]
View
40
[SID103598785]
 Toxicity in rhesus monkey assessed as induction of vaginal inflammation administered twice daily dose of 5% compound-formulated gel for first 8 weeks followed by 3-weeks rest period and subsequent once daily dose for 1 weeks measured 6 months post dose by extensive colposcopy [AID580479, Type: Literature]
View
41
[SID103598785]
 TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells [AID681134, Type: other]Multidrug resistance protein 1 [gi:238054374]
View
42
[SID103598785]
 TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells [AID681134, Type: other]Multidrug resistance protein 1 [gi:238054374]
View
43
[SID103598785]
 TP_TRANSPORTER: Daunomycin accumulation in Caco-2 cells [AID681134, Type: other]Multidrug resistance protein 1 [gi:238054374]
View
44
[SID26757947]
 qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore) [AID880, Type: confirmatory]RGS12 [Homo sapiens] [gi:3290016]
View
45
[SID26757947]
Potency Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 [AID1479, Type: confirmatory]thyroid hormone receptor beta [Homo sapiens] [gi:189491771]
View
46
[SID26757947]
Potency Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 [AID1479, Type: confirmatory]thyroid hormone receptor beta [Homo sapiens] [gi:189491771]
View
47
[SID26757947]
Potency Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 [AID1479, Type: confirmatory]thyroid hormone receptor beta [Homo sapiens] [gi:189491771]
View
48
[SID26757947]
Potency qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 [AID1469, Type: confirmatory]thyroid hormone receptor beta [Homo sapiens] [gi:189491771]
View
49
[SID26757947]
Potency qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 [AID1469, Type: confirmatory]thyroid hormone receptor beta [Homo sapiens] [gi:189491771]
View
50
[SID26757947]
Potency qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2 [AID1469, Type: confirmatory]thyroid hormone receptor beta [Homo sapiens] [gi:189491771]
View